ArticleCureus2024
Optimizing Granulocyte-Colony Stimulating Factor Dosing Scheme in Healthy Stem Cell Donors for Allogenic Transplantation: A Retrospective Cohort Study of Single Dose vs. Split Dose.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives The optimal dosing schedule strategy for granulocyte colony-stimulating factor (G-CSF) in healthy stem cell donors remains controversial. This study aimed to compare the efficacy of once-daily versus twice-daily G-CSF administration in allogeneic stem cell donors. Materials and methods We retrospectively analyzed data from 388 healthy unrelated donors (282 males, 106 females) who underwent stem cell mobilization at our center between September 2018 and June 2022. Donors received daily either a single dose of 10 μg/kg/day or two doses of 5 μg/kg/day of filgrastim. Results The split-dose group had significantly higher CD34+ cell counts in peripheral blood (p<0.001), total collected CD34+ cell counts (p<0.001), and total collected CD34+ cell counts per donor body weight (p<0.001) than the single-dose group with one apheresis procedure on the fifth day of GCSF. Multivariable analysis revealed that split-dose G-CSF administration was independently associated with higher peripheral blood CD34+ cell count (p<0.001) and higher total collected CD34+ cell count per donor body weight (p<0.001). Coincidentally, the split-dose group also had higher rates of catheter use (p = 0.003). Conclusion Split-dose G-CSF administration led to better stem cell mobilization than once-daily dosing. These findings contribute to optimizing G-CSF regimens for allogeneic stem cell donation, potentially improving transplantation outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.